411 related articles for article (PubMed ID: 35264774)
1. Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.
Sager RA; Backe SJ; Ahanin E; Smith G; Nsouli I; Woodford MR; Bratslavsky G; Bourboulia D; Mollapour M
Nat Rev Urol; 2022 May; 19(5):305-320. PubMed ID: 35264774
[TBL] [Abstract][Full Text] [Related]
2. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
Roulin D; Demartines N; Dormond O
Biochem Soc Trans; 2011 Apr; 39(2):492-4. PubMed ID: 21428926
[TBL] [Abstract][Full Text] [Related]
3. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Cetin B; Wabl CA; Gumusay O
Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
[TBL] [Abstract][Full Text] [Related]
4. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
5. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.
Juengel E; Engler J; Natsheh I; Jones J; Mickuckyte A; Hudak L; Jonas D; Blaheta RA
BMC Cancer; 2009 May; 9():161. PubMed ID: 19473483
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-Dependent Kinase 4/6 Inhibitors: A Potential Breakthrough Therapy for Malignancies of Gastrointestinal Tract.
Zeng F; Zhou Y; Khowtanapanich T; Saengboonmee C
In Vivo; 2022; 36(4):1580-1590. PubMed ID: 35738597
[TBL] [Abstract][Full Text] [Related]
7. Renal Cell Cancer - Insights in Drug Resistance Mechanisms.
Aweys H; Lewis D; Sheriff M; Rabbani RD; Lapitan P; Sanchez E; Papadopoulos V; Ghose A; Boussios S
Anticancer Res; 2023 Nov; 43(11):4781-4792. PubMed ID: 37909991
[TBL] [Abstract][Full Text] [Related]
8. Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition.
Saliby RM; Saad E; Labaki C; Xu W; Braun DA; Viswanathan SR; Bakouny Z
Hematol Oncol Clin North Am; 2023 Oct; 37(5):1015-1026. PubMed ID: 37385938
[TBL] [Abstract][Full Text] [Related]
9. The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age.
Huang JJ; Hsieh JJ
Semin Nephrol; 2020 Jan; 40(1):28-41. PubMed ID: 32130964
[TBL] [Abstract][Full Text] [Related]
10. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
11. Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma.
Reddy GK; Mughal TI; Rini BI
Clin Genitourin Cancer; 2006 Sep; 5(2):110-3. PubMed ID: 17026798
[TBL] [Abstract][Full Text] [Related]
12. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.
Parikh M; Lara PN
Annu Rev Med; 2018 Jan; 69():209-221. PubMed ID: 29144835
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitors in advanced renal cell carcinoma.
Voss MH; Molina AM; Motzer RJ
Hematol Oncol Clin North Am; 2011 Aug; 25(4):835-52. PubMed ID: 21763970
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of mTor inhibitors for renal cancer.
Ghidini M; Petrelli F; Ghidini A; Tomasello G; Hahne JC; Passalacqua R; Barni S
Expert Opin Investig Drugs; 2017 Nov; 26(11):1229-1237. PubMed ID: 28952411
[TBL] [Abstract][Full Text] [Related]
15. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
17. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function.
Mielczarek Ł; Brodziak A; Sobczuk P; Kawecki M; Cudnoch-Jędrzejewska A; Czarnecka AM
Cancer Chemother Pharmacol; 2021 Jun; 87(6):723-742. PubMed ID: 33768301
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
19. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
20. Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma.
Jaimes EA
Semin Nephrol; 2020 Jan; 40(1):49-58. PubMed ID: 32130966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
